• Agios Pharmaceuticals targets non-GAAP profitability in 2028, driven by revenue growth and cost discipline.
• R&D headcount reductions will exceed 35%, or 100 roles, in 2026.
• Third-quarter mitapivat net revenue reached $55.4 million, 4.3 times the year-earlier level, driven by the thalassemia launch.
• Cash, cash equivalents and marketable securities totaled $907 million as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.